Entry into a Material Definitive Agreement. On August 31, 2026, SRX Global Inc., a Delaware corporation (the “Company”) issued a press release announcing that it had completed a secured financing transaction with CERo Therapeutics Holdings, Inc. (“CERO”). In connection with the transaction, CERO issued to the Company a Consolidated Senior Secured Promissory Note having an original issue date of August 27, 2026 (the “Note”). The Note consolidates certain outstanding convertible grid promissory…

Unregistered Sales of Equity Securities. The information provided in

Entry into a Material Definitive Agreement. Private Placement Securities Purchase Agreement On August 27, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Investors”) named therein. Pursuant to the Securities Purchase Agreement, the Company sold 3,579 shares of the Company’s Series C convertible preferred stock, par value $0.001 per share (the “Series C Pref…

Results of Operations and Financial Condition On August 13, 2026, SRX Global Inc., a Delaware corporation (the “Company”), announced its financial results for the fiscal third quarter ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 Cautionary Note Regarding Forward-Looking Statements. This Current Report on Form 8-K contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Ma…

Unregistered Sales of Equity Securities. Private Placement Additional Closing under Securities Purchase Agreement As previously announced, on March 16, 2026, SRX Global Inc. (f/k/a SRx Health Solutions, Inc.), a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein (the “Investors”). Pursuant to the Securities Purchase Agreement, up to 10,000 shares of the Company’s Series B conv…

Unregistered Sales of Equity Securities. Private Placement Additional Closing under Securities Purchase Agreement As previously announced, on March 16, 2026, SRX Global Inc. (f/k/a SRx Health Solutions, Inc.), a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein (the “Investors”). Pursuant to the Securities Purchase Agreement, up to 10,000 shares of the Company’s Series B conv…

Entry into a Material Definitive Agreement. As previously disclosed, on March 16, 2026, SRX Global Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein. Pursuant to the Securities Purchase Agreement, up to 10,000 shares of the Company’s Series B convertible preferred stock, par value $0.001 per share (the “Series B Preferred Stock”) and accompanying warrants (“Warrants”)…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On July 15, 2026, SRX Global Inc. (the “ Company ”) received a notice from the NYSE American (“ NYSE ”) that NYSE has determined the Company is back in compliance with all of the NYSE American LLC continued listing standards set forth in Part 10 of the NYSE American Company Guide (the “ Company Guide ”). Specifically, the Company has resolved the continued listing deficiency with respect to Sec…

of this Current Report shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements…

Regulation FD Disclosure Cash Dividend On July 8, 2026, SRX Global Inc. (the “ Company ”) issued a press release announcing that the Company’s Board of Directors (the “ Board ”) has approved a one-time cash dividend of $0.05 per share on common stock outstanding to shareholders of record at the close of business on July 22, 2026 (the “ Record Date ”), and that the dividend will be paid on or about August 3, 2026 to shareholders of record on Record Date. A copy of the press release is attached…

of this Current Report shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-Looking Statements…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On March 23, 2026, the Company was informed by the NYSE American LLC (the “NYSE American”) via telephone that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide, notifying the Company that its stock has been selling for a low price per share for a substantial period of time and closed below $0.10 on June 23…

Regulation FD Disclosure. Closing of Share Exchange Transaction On June 18, 2026, SRx Health Solutions, Inc. (NYSE: SRXH) (the “ Company ”) issued a press release (the “ Press Release ”) announcing that it has completed the transaction (the “ Transaction ”) with EMJ Crypto Technologies Inc., a corporation organized under the laws of Ontario, Canada (“ EMJC ”), pursuant to the previously announced Share Exchange and Asset Transfer Agreement, dated December 16, 2025, and amended on March 11, 20…

Entry into a Material Definitive Agreement. Private Placement Securities Purchase Agreement On March 16, 2026, SRx Health Solutions, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein. Pursuant to the Securities Purchase Agreement, up to 10,000 shares of the Company’s Series B convertible preferred stock, par value $0.001 per share (the “Series B Preferred Stock”) and…

Unregistered Sales of Equity Securities. The information provided in

Entry into a Material Definitive Agreement. As previously disclosed, on July 7, 2025, the Company entered into a Securities Purchase Agreement (the “Note Purchase Agreement”) by and among the Company and certain accredited investors named therein (the “Note Investors”), pursuant to which the Company issued and sold to the Note Investors (i) a new series of senior secured convertible notes (the “Notes”) with an aggregate original principal amount of $7,650,000, subject to an original issue dis…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On February 18, 2026, SRx Health Solutions, Inc. (the “Company”) received a public warning letter (the “Letter”) from the NYSE Regulation Staff of the New York Stock Exchange (the “Exchange”) notifying the Company that it failed to comply with Sections 301 and 713 of the NYSE American LLC Company Guide (the “Company Guide”). The Letter relates to the issuance of approximately 7.5 million shares…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 6, 2026, SRx Health Solutions, Inc. (the “Company”), received a notice from the NYSE American (“NYSE”), that NYSE has accepted the Company’s plan to regain compliance with Sections 1003(a)(i) and (ii) of the NYSE American Company Guide. As previously disclosed, NYSE notified the Company on October 14, 2025, that the Company had fallen below the NYSE’s continued listing standard requ…

Entry into a Material Definitive Agreement. On December 16, 2025, SRx Health Solutions, Inc. (the “Company”) entered into a Share Exchange and Asset Transfer Agreement (the “Transfer Agreement”), as unanimously approved by the Board, by and among the Company, EMJ Crypto Technologies Inc., a corporation organized under the laws of Ontario, Canada (“EMJC”), CCC Crypto Corp., a Delaware corporation (“DelawareCo”), and the transferors named therein (the “Transferors”). Upon the terms and subject…

Director — Sammy Dorf: Sammy Dorf was appointed as a Director of SRx Health Solutions, Inc.

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information provided in

Entry into a Material Definitive Agreement. Private Placement Securities Purchase Agreement On October 27, 2025, SRx Health Solutions, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain accredited investors named therein. Pursuant to the Securities Purchase Agreement, up to 38,070 shares of the Company’s Series A convertible preferred stock, par value $0.001 per share (the “Series A Preferred Stock”) an…

Director — Lionel F. Conacher, David Allen White: Voluntary resignation of directors with no successor mentioned.

Unregistered Sales of Equity Securities. The information provided in

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing On October 14, 2025, SRx Health Solutions, Inc, a Delaware corporation. (the “Company”) received a written notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) indicating that the Company is not in compliance with the NYSE American continued listing standard set forth in Section 1003(a)(ii) of the NYSE American Company Guide (“Section 1003(a)(ii)”). Section 1003(a)(ii) require…